MTOR and interstitial lung disease: A retrospective analysis of patients with advanced cancer enrolled into Phase 1 clinical trials in a single center found that HP was the most commonly occurring pattern among those with ILD related to treatment with phosphoinositide 3-kinase / AKT serine / threonine kinase / mTOR inhibitors, accounting for ~45.0% of all cases; this was closely followed by the NSIP pattern [66].